SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED

Add to a list

Inactive Instrument

SciClone Pharmaceuticals (Holdings) Limited Stock OTC Markets

SCCPF

KYG4271B1023

Latest news : SciClone Pharmaceuticals (Holdings) Limited

05-28	Cumberland Pharmaceuticals Launches Vibativ Injection in China in Strategic Partnership with SciClone Pharmaceuticals Limited	CI
04-29	SciClone Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
25-02-18	Cumberland Pharmaceuticals Inc. and SciClone Pharmaceuticals Limited Announce the National Medical Products Administration Approval of Cumberland's Vibativ® Injection in China	CI
24-06-27	SciClone Pharmaceuticals Limited's Equity Buyback announced on June 6, 2023 has expired.	CI
24-06-26	SciClone Pharmaceuticals Limited Announces Retirement of Wang Haixia as Non-Executive Director	CI
24-06-20	SciClone Pharmaceuticals Limited(SEHK:6600) dropped from S&P Global BMI Index	CI
24-05-16	Sciclone Pharmaceuticals Limited Announces Change of Address of Principal Place of Business in Hong Kong	CI
24-04-18	Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31	MT
24-04-01	SciClone Pharmaceuticals Logs 31% Increase in 2023 Profit	MT
24-03-28	Sciclone Pharmaceuticals Limited Announces Executive Changes	CI
24-03-28	Tranche Update on SciClone Pharmaceuticals Limited's Equity Buyback Plan announced on June 6, 2023.	CI
24-03-28	SciClone Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-03-27	GL China Opportunities Fund IV L.P. and GL China Opportunities Fund IV L.P., managed by GL Capital Group and GL Capital Management GP L.P. agreed to acquire 66.69% stake in SciClone Pharmaceuticals Limited for HKD 7.9 billion.	CI

More news

Press Releases: SciClone Pharmaceuticals (Holdings) Limited

22-12-09	Y-mAbs' DANYELZA for the Treatment of High-Risk Neuroblastoma Approved in China	AQ
21-09-14	Y mAbs Therapeutics : mAbs Announces Priorit Review of BLA for DANELZA (naxitamab-gqgk) in China	AQ
21-07-07	Y mAbs Therapeutics : mAbs Announces NMPA Submission of BLA for DANELZA (naxitamab-gqgk) in China	AQ
21-05-14	SciClone Pharmaceuticals : FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON WEDNESDAY, JUNE 16, 2021	PU
21-05-13	SciClone Pharmaceuticals : PROPOSED ELECTION AND RE-ELECTION OF DIRECTORS AND PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES AND NOTICE OF ANNUAL GENERAL MEETING	PU

More press releases

Managers and Directors: SciClone Pharmaceuticals (Holdings) Limited

Manager	Title	Age	Since
Hong Zhao CEO	Chief Executive Officer	61	2020-05-31
Rong Rong Pan DFI	Director of Finance/CFO	48	2023-04-27
Min Zhong CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Rong Rong Pan BRD	Director/Board Member	48	2023-04-27
Hong Zhao BRD	Director/Board Member	61	2020-05-31
Zhen Fu Li CHM	Chairman	62	2020-05-31

More insiders

SciClone Pharmaceuticals (Holdings) Ltd is a company principally engaged in the provision of treatment plans for tumors and severe infectious diseases. The Company and its subsidiaries are principally engaged in developing and commercializing a portfolio of marketed products as well as pipelines with potential in their focused therapeutic areas including oncology and severe infection. The Companyâ€™s main products comprise Zadaxin, Zometa, Oravig, Angiomax, Endoxan, Holoxan, Cytosafe, Farlutal, Campto and Vizimpro. The Companyâ€™s pipeline products include ORSERDU, Vaborem, Vibativ, RRx-001 and Omburtamab. The Companyâ€™s products are mainly used in fields such as tumors, urinary tract infections, and skin and soft tissue infections. The Company mainly conducts its businesses in the domestic market.

Employees

1,050

Sector

Pharmaceuticals

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED	-.--%	-.--%	-	-	1.47B
REGENERON PHARMACEUTICALS, INC.	+1.59%	+2.85%	+39.32%	+0.52%	78.32B
SAMSUNG BIOLOGICS CO.,LTD.	+2.77%	+4.78%	-0.98%	+28.10%	51.1B
UCB	-0.84%	+0.09%	+20.92%	+175.02%	49.18B
CSL LIMITED	-0.13%	+7.42%	-49.33%	-50.09%	44.71B
BIOGEN INC.	+0.80%	+2.46%	+59.13%	-24.15%	30.72B
INCYTE CORPORATION	+1.84%	+0.87%	+53.80%	+86.83%	24.44B
MODERNA, INC.	+9.86%	+7.94%	+126.53%	-40.68%	23.62B
INNOVENT BIOLOGICS, INC.	+4.29%	+9.40%	+3.95%	+230.49%	21.05B
SWEDISH ORPHAN BIOVITRUM AB	+1.66%	-3.70%	+66.13%	+121.72%	16.61B
Average	+2.18%	+4.08%	+35.50%	+58.64%	37.75B
Weighted average by Cap.	+1.87%	+4.29%	+26.94%	+44.55%